Contact Information
Steven T. Rosen, M.D.
  • Provost and Chief Scientific Officer
  • Director, NCI Designated Comprehensive Cancer Center
  • Irell & Manella Cancer Center Director's Distinguished Chair
  • Director, Beckman Research Institute

Primary Specialties

Departments/Division/Program

Biography

Steven T. Rosen, M.D., is provost and chief scientific officer for City of Hope and a member of City of Hope’s Executive Team. He also is director of the Comprehensive Cancer Center and holds the Irell & Manella Cancer Center Director's Distinguished Chair, and he is director of Beckman Research Institute (BRI) and the Irell & Manella Graduate School of Biological Sciences.
 
Rosen sets the scientific direction of City of Hope, shaping the research and educational vision for the biomedical research, treatment and education institution. Working closely and collaboratively with City of Hope’s scientists, clinicians and administrative leaders, he develops strategies that contribute to the organization’s mission.

As director of BRI, he works with faculty across the institution to help shape and direct the scientific vision for BRI while leading the vital basic and translational research that is fundamental to our strategic plan and mission. He focuses on opportunities for expanding and integrating our research initiatives; recruiting and leading talented scientists; helping our talented researchers achieve national and international recognition; and promoting our national standing as a premier scientific organization.  
 
Prior to joining City of Hope, Rosen was the Genevieve Teuton Professor of Medicine at the Feinberg School of Medicine at Northwestern University in Chicago. He served for 24 years as director of Northwestern’s Robert H. Lurie Comprehensive Cancer Center. Under his leadership, the center received continuous National Cancer Institute (NCI) funding beginning in 1993 and built nationally recognized programs in laboratory sciences, clinical investigations, translational research and cancer prevention and control. The center attained comprehensive status in 1997.
 
Rosen has published more than 400 original reports, editorials, books and book chapters. His research has been funded by the National Cancer Institute, American Cancer Society, Leukemia & Lymphoma Society of America and Multiple Myeloma Research Foundation. He also has served as an adviser for several of these organizations and on the external advisory boards of more than a dozen NCI-designated Comprehensive Cancer Centers. He is the current editor-in-chief of the journal Cancer Treatment & Research.
 
Recognized as one of the Best Doctors in America, Rosen is a recipient of the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital and the Man of Distinction Award from the Israel Cancer Research Fund. He earned his bachelor’s degree and medical degree with distinction from Northwestern University.
 

Professional Experience

2014-present, Provost and Chief Scientific Officer, City of Hope, Duarte, CA
1989-2014, Director, The Robert H. Lurie Comprehensive Cancer Center of Northwestern University,  Chicago, IL
1989-2014, Director of Cancer Programs Northwestern Memorial Hospital, Chicago, IL
1989-2014, Genevieve Teuton Professor of Medicine, Feinberg School of Medicine at Northwestern  University, Chicago, IL
1981-2014, Attending Physician Northwestern Memorial Hospital, Chicago, IL
1982-1986 Assistant Professor, Department of Medicine, Northwestern Univ. Medical School, Chicago, IL
1981-1987, Staff Physician, Division of Hematology/Oncology, Veterans Administration Lakeside  Medical Center, Chicago, IL
1981, Associate, Department of Medicine, Northwestern Univ. Medical School, Chicago, IL
 
 
 

Education

EDUCATION
1976, M.D., Northwestern University Medical School, Chicago, IL
1972, B.M., Honors Program, Northwestern University, Evanston, IL
 
TRAINING
1979-1981, Fellowship in Hematology/Oncology, National Cancer Institute, Bethesda, MD
1977-1979, Residency in Internal Medicine, Northwestern Memorial Hospital, Chicago, IL

Honors and Awards

HONORS
1969-1972, Honors Medical Program, Northwestern University
1976, Alpha Omega Alpha
1976, M.D. with Distinction, Northwestern University
1986, Participant, President's Cancer Panel, Chicago
1986, Member, Central Society for Clinical Research
2011, Member, NCI Fredericks Scientific Advisory Committee
2012, Chairman, Leukemia & Lymphoma Society of America Medical/Science Committee
 
AWARDS
1994, Alumni Merit Award, Northwestern University
1994, Martin Luther King Humanitarian Award, Northwestern Memorial Hospital
2011, Man of Distinction Award, Israel Cancer Research Fund

Research

Dr. Rosen is a clinician and scientist with expertise in the diagnosis and treatment of blood cancers, particularly Non-Hodgkin lymphoma, cutaneous lymphoma, chronic lymphocytic leukemia (CLL) and multiple myeloma. He has been a pioneer in the use of biological therapies including:
 
  • monoclonal antibodies and recombinant toxins that can specifically target cancer cells
  • apoptosis inducers, proteasome inhibitors and metabolism inhibitors to promote cancer cell death
  • RNA based analogs and cell signaling regulators that can interfere with cancer growth processes
  • vaccines, interferons and cytokines that can trigger an immune response against cancer cells
  • angiogenesis inhibitors to prevent cancer from growing new blood vessels
  • transcriptional regulators and antisense compounds to activate or silence certain genes in cancer and normal cells
  • hormone therapies
     
He has conducted numerous clinical trials and is recognized as one of the leading figures in “bench to bedside” research by rapidly transforming scientific breakthroughs into promising therapies.
 
Active
 
P30 CA033572 (Rosen)  12/01/12 - 11/30/17
NIH/NCI
Cancer Center Support Grant
The Cancer Center Support Grant provides support for administration and infrastructure for the City of Hope comprehensive Cancer Center.  Dr. Rosen is the Cancer Center Director.  The goals of the Cancer Center Support Grant are to conduct and support cancer research and to coordinate and integrate cancer–related activities of the institution, including community outreach initiatives; to develop and conduct cancer education programs; to promote and participate in state-of-the-art care of cancer center patients at the City of Hope and implement the initiatives in cancer prevention and control research.  These goals are accomplished through the activities of the 5 established programs and 10 shared resources
 
U54 CA151880-04 (Mirkin/Rosen) 09/21/10 - 07/31/15
NIH/NCI
Nanomaterials for Cancer Diagnostics and Therapeutics
The Northwestern University Center for Cancer Nanotechnology Excellence (NU-CCNE) will draw upon NU’s outstanding research strengths in the areas of cancer research, nanoscience, bioimaging and nano-tool development. The long-term objective of the NU-CCNE is to design and test nanomaterials and nanodevices for application in the clinic, ultimately facilitating the translation of novel and innovative nanoscale technologies that significantly improve cancer prevention, detection, diagnosis, and treatment.
 
 

Publications

 

  1. Ghias K, Ma C, Gandhi V, Krett N, Rosen ST. 8-Amino-Adenosine induces loss of phosphorylation of p38 MAPK, ERK1/2, and Akt Kinase: Role in induction of apoptosis in multiple myeloma. Molecular Cancer Therapeutics, 4:569-577, 2005 Apr.
     
  2. Shanmugam M, McBrayer SK, Qian J, Raikoff K, Avram MJ, Singhal S, Gandhi V, Schumacker PT, Krett NL, Rosen ST. Targeting Glucose Consumption and Autophagy in Myeloma with the Novel Nucleoside Analogue 8-Amino-Adenosine. J. Biol. Chem.284(39):26816-30, 2009 Sep.
     
  3. Dennison  J, Shanmugam M, Krett N, Medeiros J, Neelapu S, Rosen, ST, Gandi V. 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. Blood 116:  5622-5630, 2010 Dec 16.
     
  4. McBrayer, SK., Yarrington, M., Qian, J., Feng, G., Shanmugam, M., Gandhi, V., Krett, NL., and Rosen, ST.  Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms.  PLoS ONE, Vol 7, Issue 7, July 2012.
     
  5. McBrayer S, Cheng J, Singhal S, Krett NL, Rosen ST, Shanmugam M. Multiple Myeloma exhibits Novel Dependence on GLUT4, GLUT8, and GLUT11: Implications for Glucose Transporter-Directed Therapy. Blood First Edition Paper, 3/27/2012:DOI 10.1182/Blood-2011-09-3377846
     
  6. Cheng JC, McBrayer SK, Rosen ST, Shanmugam M. Expression and Phosphorylation of the AS160_v2 Splice Variant supports GLUT4 Activationand the Warburg Effect in Multiple Myeloma. Cancer Metabolism 2013 , 1:14, 29 May 2013
     
  7. Adekola K U.A., Aydemir SD, Ma S, Zhou Z, Rosen ST, Shanmugam M, Investigating and Targeting Chronic Lymphocytic Metabolism with the HIV Protease Inhibitor Ritonavir and Metformin.  Leukemia & Lymphoma, 2014 Aug 4:1-10
     
  8. Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC, Rosen ST. Characterizations Of The MM.1 Human Multiple Myeloma (MM) Cell Lines: A Model System To Elucidate The Characteristics, Behavior, and Signaling Of Steroid-sensitive And Resistant MM Cells.  Experimental Hematology, 31(4):271-82, 2003 Apr.
     
  9. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R; European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood  1;112(5):1600-9, 2008 Sept.
     
  10. Tessel MA, Benham AL, Krett NL, Rosen ST, Gunaratne PH. Role for MicroRNAs in Regulating Glucocorticoid Response and Resistance in Multiple Myeloma. Horm Cancer. 2011 Jun;2(3):182-9.
     
  11. Lesovaya E, Yemelyanov A, Kirsanov K, Popa A, Belitsky G, Yakubovskaya M, Gordon L, Rosen ST, Budunova I. Combination of the Glucocorticoid Receptor Selective Activator - Compound A with Proteasome Inhibitor as a Novel Strategy for Chemotherapy of Hemtalogical Malignancies. Cell Cycle, 12:1, pp 133-144, Jan 2013.
     
  12. Querfeld C, Kuzel TM, Guitart J, Rizvi M, Sabharwal SS, Krett N, Rosen ST. The selective protein kinase C-beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 126:1641-1647, 2006 Jul.
     
  13. Querfeld C, Kuzel T, Kim Y, Porcu P, Rook A, Music A, Mark L, Pinter-Brown L, Duvic M, Hamid O, Lin B, Bian Y, Boye M, Day J, Rosen ST. Multicenter Phase 2 Trial of Enzastaurin Monotherapy in Patients with Relapsed or Refractory Advanced Cutaneous T-Cell Lymphoma(CTCL). Leukemia & Lymphoma  2011 Aug;52(8):1474-80.
     
  14. Rovedo M, Krett N, Rosen ST. Inhibition of Glycogen Sunthase Kinase-3 Increases the Cytotoxicity of Enzastaurin. Journal of Investigative Dermatology 2011 Jul;131(7):1442-9. Doi:10.1038/jid.2011.70
     
  15. Bliss-Moreau M, Coarfa C, Gunaratne P, Guitart, J, Krett N, Rosen ST.  Identification of p38 as a therapeutic target for treatment of  Sézary Syndrome.  Journal of Investigative Dermatology 2014 Aug 22.
 

Location

City of Hope - Main campus
1500 E. Duarte Rd.
Duarte, CA 91010

Media Expertise

  • Hematologic malignancies
  • Leukemia
  • Lymphoma
  • Multiple Myeloma